- Home
- KOPN vs AVIR Comparison
KOPN vs AVIR Comparison
Compare KOPN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOPN | AVIR |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 399.3M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KOPN | AVIR |
|---|---|---|
| Price | $4.74 | $5.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.69 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 4.4M | 354.3K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.03 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $1,530,311.00 | ★ $351,367,000.00 |
| Revenue This Year | $50.07 | N/A |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 46.53 | N/A |
| 52 Week Low | $1.81 | $2.78 |
| 52 Week High | $6.61 | $6.45 |
Technical Indicators
Market Signals| Indicator | KOPN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 64.13 |
| Support Level | $4.38 | $5.13 |
| Resistance Level | $5.53 | $5.83 |
| Average True Range (ATR) | 0.35 | 0.26 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 58.21 | 82.29 |
Price Performance
Historical ComparisonAbout KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.